The company exploits a constantly evolving portfolio of patents that protects the various aspects of the processes under development. Some patent applications have already been published. Additional complementary patent applications are continuously being filed; they concern the design of the whole metabolic pathway, its improvements, and parallel pathways leading to the synthesis of other hydrocarbons as well as specific steps of the process. The Company holds exclusive rights on this entire portfolio of patents that are either owned by the Company, or by Philippe Marlière through his holding Scientist of Fortune, or co-owned by Scientist of Fortune and Global Bioenergies. In the two latter instances, license agreements that control the transfer of exclusive exploitation rights to Global Bioenergies are in place.
